title: Vitreous cefazolin levels after intravenous injection. Effects of inflammation, repeated antibiotic doses, and surgery.
abstract: We devised a standardized rabbit model of intraocular inflammation using heat-killed Staphylococcus epidermidis as the inducing organism. We applied this model to study the effects of (1) inflammation, (2) repeated antibiotic doses, and (3) surgical status of the eye on cefazolin levels in the vitreous cavity after intravenous administration. Intravenous cefazolin sodium, 50 mg/kg, was administered every 8 hours for 48 hours. Eyes were harvested for assay of vitreous cavity antibiotic levels at various intervals from 1 to 49 hours. Drug levels were compared in inflamed and noninflamed eyes under both phakic and aphakic/vitrectomized conditions. At 1 hour, levels in phakic specimens were 3.0 mg/L in inflamed eyes vs undetectable in noninflamed eyes (P less than .01), but progressively increased to 10.6 mg/L at 49 hours (P less than .02) in inflamed eyes only. Levels in aphakic/vitrectomized eyes at 1 hour were 6.7 mg/L in inflamed eyes vs 4.2 mg/L in noninflamed eyes (P less than .1), but progressively increased to 24.9 mg/L at 49 hours (P less than .001) in inflamed eyes only. Levels at 49 hours in inflamed phakic and inflamed aphakic/vitrectomized eyes were well above the minimum inhibitory concentrations for organisms termed sensitive to cefazolin. We would conclude, therefore, that repeated doses of intravenous cefazolin may play an important adjunctive role in the treatment of endophthalmitis.
authors.affiliation: Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA 30322.
authors.forename: D F
authors.initials: DF
authors.lastname: Martin
authors.forename: L A
authors.initials: LA
authors.lastname: Ficker
authors.forename: H A
authors.initials: HA
authors.lastname: Aguilar
authors.forename: S K
authors.initials: SK
authors.lastname: Gardner
authors.forename: L A
authors.initials: LA
authors.lastname: Wilson
authors.forename: T A
authors.initials: TA
authors.lastname: Meredith
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000867:Anterior Chamber / Q000276:immunology / Q000378:metabolism; D001035:Aphakia / Q000276:immunology / Q000378:metabolism*; D002437:Cefazolin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D007249:Inflammation / Q000378:metabolism; D007275:Injections, Intravenous; D010865:Pilot Projects; D011817:Rabbits; D013212:Staphylococcus epidermidis / Q000276:immunology; D014605:Uveitis / Q000276:immunology / Q000378:metabolism*; D014821:Vitrectomy; D014822:Vitreous Body / Q000378:metabolism*
chemical_list: D002437:Cefazolin